TacticScaleWhat Biocytogen Pharmaceuticals (Beijing) Does & How It Makes Money (2315.HK)
Updated October 2026 · reflects Biocytogen Pharmaceuticals (Beijing)'s latest reported financials
Chinese biotech offering gene-editing, animal models, and antibody drug discovery. It earns revenue from fee-based gene-editing, pharmacology testing, and sales of animal models to research customers, and seeks to monetize its antibody discoveries and drug candidates through licensing and collaboration deals with partners such as RemeGen and Chipscreen NewWay.
How Biocytogen Pharmaceuticals (Beijing) makes money
It earns revenue from fee-based gene-editing, pharmacology testing, and sales of animal models to research customers, and seeks to monetize its antibody discoveries and drug candidates through licensing and collaboration deals with partners such as RemeGen and Chipscreen NewWay.
What Biocytogen Pharmaceuticals (Beijing) does
Biocytogen, founded in 2008 and headquartered in Beijing, combines a pre-clinical research services business with in-house antibody drug development. It reports across five segments—Gene-Editing, Pharmacological Efficacy, Model Animals, Antibody Development, and Other—and serves customers in China, the United States, and internationally with customized gene-edited animals and cells, drug efficacy and toxicity studies, and genetically engineered, disease, and aged animal models. On the drug side, it uses its own antibody discovery platforms to find candidates in oncology and autoimmune disease. Its pipeline includes YH001, a humanized anti-CTLA-4 IgG1 antibody for advanced solid tumors, and YH002, an anti-OX40 (TNFRSF4) IgG1 antibody in Phase I. The company works with partners through a collaboration with Syncromune and license agreements with RemeGen and Chipscreen NewWay Biosciences.
Products & services
- Customized gene-editing services (animals and cells)
- Genetically engineered and disease mouse models
- Pre-clinical pharmacology efficacy and toxicity services
- Antibody discovery platforms
- YH001 (anti-CTLA-4 antibody)
- YH002 (anti-OX40/TNFRSF4 antibody)
What is Biocytogen Pharmaceuticals (Beijing) worth?
On an owner-earnings DCF, Biocytogen Pharmaceuticals (Beijing)'s most-likely value is about HK$4 versus a recent price near HK$61 (1565% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~HK$1) with a margin of safety — so the honest verdict here is “Stretched — richly priced.” Fair value earns its keep only at the extremes, not in the wide middle.
Today's $61 is above even the optimistic Bull case ($12) — the market expects faster, longer growth than modeled here. Expensive unless that extra growth actually shows up.
⚠ Capital-intensive — this business reinvests heavily, so free cash flow runs well below its earnings. Fair value here is built on free cash flow, which understates owner earnings for reinvestment-heavy companies — read it as conservative.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Biogen (BIIB) · Bio-Techne (TECH) · BrightGene Bio-Medical Technology (688166.SS) · Bio-Thera Solutions (688177.SS)